The safety and efficacy of cefepime, a new broad-spectrum, semisynthetic parenteral 
patient and loose bowel movements and increased transaminases in the other patient. Cefepime appeared to be well tolerated in humans and was effective against a wide range of isolates, including S. aureus and P. aeruginosa.
Cefepime (BMY 28142) is a new aminothiazolemethoximino cephalosporin antibiotic with an extended spectrum of activity against gram-negative organisms, including multiantibiotic-resistant Pseudomonas aeruginosa, with preservation of activity against gram-positive organisms, including Staphylococcus aureus (1, (2) (3) (4) . It is active therapeutically in mouse (3) , rabbit (7) , and rat (5) midstream urine, and needle aspirates or swabs of skin and soft tissue infections.
Response to therapy. Patients were evaluated for efficacy and adverse reactions by standard methods that included history and physical and laboratory examination. Seven doses of cefepime had to be received for the patient to be considered for evaluation of efficacy. Cultures of clinically pertinent sites were obtained during treatment and 1 (3 for urinary tract infections) to 14 days after completion of cefepime therapy. For pneumonia, pre-and posttreatment chest radiographs were obtained.
A clinical response was considered satisfactory if all signs or symptoms of infection had resolved or improved at the time of posttreatment evaluation. The response was considered a failure when a clinical sign or symptom persisted unabated or increased or new signs or symptoms were evident at the time of posttreatment evaluation. Superinfection was diagnosed when the original pathogen had been eradicated, a new pathogen was isolated from the original site of infection, and clinical signs of infection were present. Symptoms routinely evaluated included fever; chills; pain at pertinent sites; dysuria; urinary urgency, frequency, burning and hesitancy; cough; sputum production; and dyspnea. Signs included rales; chest retractions; tachypnea; diminished breath sounds; skin ulceration, exudate, erythema, edema, odor, and induration; and lymphangitis. The symptoms and signs were evaluated at least every 3 to 4 days during cefepime treatment and were scored on a four-point scale, as follows: 1, resolved; 2, improved; 3, unchanged; 4, worse with respect to the last previous evaluation.
Bacteriologic response was classified as eradication, persistence, or relapse. For respiratory and skin infections, eradication was defined as failure to culture the pretreatment causative pathogen at posttreatment evaluation. For urinary tract infections, eradication was a sterile urine culture (10 1ul plated with a loop) during days 2 to 4 of cefepime treatment and at posttreatment evaluation. Persistence was defined as presence of pretreatment pathogens in during-treatment and posttreatment cultures. Relapse was indicated when duringtreatment cultures were sterile but posttreatment cultures yielded the original pathogen.
RESULTS
The large majority of patients had either respiratory infections (all bacterial pneumonias) or skin or soft tissue infections (Table 1 ). Of 65 clinically evaluable patients, 64 (98%) had a satisfactory response. The single failure occurred in a patient with Enterobacter cloacae pneumonia.
Haemophilus spp. and Streptococcus pneumoniae were the most common pulmonary pathogens (Table 2) . Underlying diseases that predisposed to bacterial pneumonia were common, as 23 of 42 patients had chronic obstructive lung disease, 11 had congestive heart failure, 8 had cancer of the (7) P. aeruginosa (7) S. aureus (2) E. coli (4) Other streptococcal spp.
Klebsiella spp. (4) (2) Enterobacter spp. (3) Proteus mirabilis (1) Serratia marcescens (1) B. catarrhalis (1) Neisseria spp. (4) Skin and/or S. aureus (6) P. aeruginosa (2) soft tissue Coagulase-negative staph Klebsiella spp. (2) ylococci (3) E. coli (1) Beta-hemolytic strepHaemophilus influenzae (1) tococcal spp. (5) Serratia marcescens (1) A. odorans (1) Morganella morganii (1) Proteus mirabilis (1) Urine P. aeruginosa (1) Proteus mirabilis (1) E. coli (1) well with vancomycin, nafcillin, or clindamycin. The fifth patient presented with fever, sweating, and flank pain and was enrolled as having a urinary tract infection. Since the urine culture was sterile, he was dropped from the study after one dose of cefepime. He was discovered to have pyonephrosis due to blockage of a ureter with a stone, and Escherichia coli was cultured from urine collected from the nephrostomy tube. He responded well to other antibiotics and nephrostomy drainage. The microbiologic responses are summarized in Tables 2  and 3 . Haemophilus spp. (10 cases) and S. pneumoniae (8 cases) were the most frequent respiratory pathogens. Recovered less frequently were S. aureus (2 cases); Pseudomonas aeruginosa (7 cases); E. coli (4 cases); Klebsiella spp. (4 cases); Neisseria spp. (4 cases); Enterobacter spp. (3 cases); and Proteus mirabilis, Serratia marcescens, and Branhamella catarrhalis (1 case each). S. aureus and betahemolytic streptococci were the most frequent skin and soft tissue pathogens. The MIC ranges (micrograms per milliliter) for all pathogens were as follows: S. aureus, 2 to 8 (n = 13); coagulase-negative staphylococci, 0.5 to 16 (n = 5); S. pneumoniae, 0.015 to 0.125 (n = 5); beta-hemolytic streptococci, 0.03 to 0.125 (n = 5); Enterococcus spp., 16 to 128 (n = 3); P. aeruginosa, 1 to 8 (n = 9); E. coli, 0.03 to 0.5 (n = 5); Proteus mirabilis, 0.06 to 8 (n = 4); Klebsiella spp., 0.03 to 0.5 (n = 4); Serratia spp., 0.125 to 4 (n = 3); Enterobacter spp., 0.03 to 0.5 (n = 3).
Follow-up cultures were obtained in all patients with urinary tract infections, 65% of patients with skin and soft tissue infections, and 83% of patients with pneumonia. In cases of patients who did not have follow-up cultures, either they were unable to produce purulent sputum or their skin disease had resolved. The relatively high numbers of persistent isolates in skin and soft tissue infections were due entirely to three patients with chronic skin defects that were cultured although signs or symptoms of infection were absent or substantially diminished. The single relapse occurred in a quadriparetic patient with a urinary tract infection, who may have had a neurogenic bladder but did not have an indwelling bladder catheter. E. coli, the original pathogen, was cultured in urine obtained 8 days after completion of cefepime treatment. This patient had no signs or symptoms of infection other than recurrent pyuria at the time of posttreatment culture and evaluation.
Five patients were colonized with potential pathogens as judged by cultures obtained 1 to 9 days after the end of cefepime treatment. No clinical superinfections were observed.
Only two patients were judged to have adverse reactions to cefepime. One patient treated for cellulitis had transient diarrhea on day 6 of cefepime therapy. Cefepime was stopped on day 10 with clinical and microbiologic cure. Clostridium difficile toxin (latex test) was detected in his stool, but since the diarrhea had resolved within 1 day, he was not treated for C. difficile diarrhea. In the other case, that of a patient with pneumonia, the serum glutamic pyruvic transaminase rose from an initial level of 42 IU/dl to 110 IU/dl on day 5 of cefepime therapy, and he had transient (1-day) loose bowel movements. He did not participate in follow-up. Of note, no effect of cefepime treatment on prothrombin times was detected.
DISCUSSION
This study indicates that cefepime is effective in pneumonia (predominantly community-acquired), skin and soft tissue infections due primarily to staphylococci and streptococci, and urinary tract infections at a dosage of 1 g every 12 h. Moderately severe infections were selected, since cefepime had not been used therapeutically in humans before. Cefepime was well tolerated, with only two minor adverse reactions.
The only clinical failure occurred in a patient with poor respiratory clearance mechanisms and a pneumonia due to Enterobacter cloacae. This patient subsequently responded to high dosages of cefotaxime in combination with amikacin. Possibly the dose of cefepime was too low or a synergistic combination of antibiotics was needed to successfully treat this patient. Two other patients in this study with Enterobacter pulmonary infections (one each with Enterobacter cloacae and Enterobacter aerogenes) were treated successfully with cefepime. Cefepime has bactericidal activity against most susceptible isolates, and its MICs for 90% of isolates against Enterobacter spp. are much lower than those of ceftazidime, cefotaxime, cefoperazone, and moxalactam (1, 3, 4) .
Cefepime possesses attractive properties in comparison with other new broad-spectrum cephalosporins. Cefepime maintains bactericidal activity against methicillin-susceptible S. aureus, along with broad activity against members of the family Enterobacteriaceae and P. aeruginosa (1, 2-4).
Cefepime resists hydrolysis by a number of purified Plactamases (3) and has poor affinity for P-lactamases ( 
